CL2022002695A1 - Inhibidores de rip1k - Google Patents

Inhibidores de rip1k

Info

Publication number
CL2022002695A1
CL2022002695A1 CL2022002695A CL2022002695A CL2022002695A1 CL 2022002695 A1 CL2022002695 A1 CL 2022002695A1 CL 2022002695 A CL2022002695 A CL 2022002695A CL 2022002695 A CL2022002695 A CL 2022002695A CL 2022002695 A1 CL2022002695 A1 CL 2022002695A1
Authority
CL
Chile
Prior art keywords
rip1k
inhibitors
kinase
inhibitor compounds
rip1
Prior art date
Application number
CL2022002695A
Other languages
English (en)
Inventor
Darwish Ihab
LUO Zhushou
Taylor Vanessa
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of CL2022002695A1 publication Critical patent/CL2022002695A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente descripción se describen compuestos inhibidores de quinasa, tales como los compuestos inhibidores de la proteína quinasa 1 que interactúa con el receptor (RIP1), así como también composiciones farmacéuticas y combinaciones que comprenden tales compuestos inhibidores. Los compuestos, composiciones farmacéuticas y/o combinaciones descritos pueden usarse para tratar o prevenir una enfermedad o afección asociada a quinasas, particularmente una enfermedad o afección asociada a RIP1.
CL2022002695A 2020-04-02 2022-09-30 Inhibidores de rip1k CL2022002695A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063004404P 2020-04-02 2020-04-02

Publications (1)

Publication Number Publication Date
CL2022002695A1 true CL2022002695A1 (es) 2023-08-11

Family

ID=75747027

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002695A CL2022002695A1 (es) 2020-04-02 2022-09-30 Inhibidores de rip1k

Country Status (20)

Country Link
US (2) US11584758B2 (es)
EP (1) EP4126864A1 (es)
JP (1) JP2023520046A (es)
KR (1) KR20220161433A (es)
CN (1) CN115867548A (es)
AR (1) AR121717A1 (es)
AU (1) AU2021246147B2 (es)
BR (1) BR112022019492A2 (es)
CA (1) CA3173432A1 (es)
CL (1) CL2022002695A1 (es)
CO (1) CO2022014137A2 (es)
CR (1) CR20220492A (es)
DO (1) DOP2022000215A (es)
EC (1) ECSP22076856A (es)
IL (1) IL296916A (es)
JO (1) JOP20220246A1 (es)
MX (1) MX2022012305A (es)
PE (1) PE20230560A1 (es)
TW (1) TW202204364A (es)
WO (1) WO2021203011A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI763630B (zh) * 2015-07-02 2022-05-11 瑞士商赫孚孟拉羅股份公司 雙環內醯胺及其使用方法
SG11202010913PA (en) 2018-05-03 2020-12-30 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same
PE20221628A1 (es) 2019-09-06 2022-10-19 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos
WO2021046437A1 (en) 2019-09-06 2021-03-11 Rigel Pharmaceuticals, Inc. Rip1 inhibitory compounds and methods for making and using the same
MX2022010693A (es) * 2020-02-28 2022-09-26 Univ Texas Compuestos, composiciones y metodos para inhibidores de la proteina quinasa que interactua con el receptor i para el tratamiento de enfermedades.
AR122703A1 (es) 2020-07-01 2022-09-28 Rigel Pharmaceuticals Inc Inhibidores de rip1k
WO2023137035A1 (en) * 2022-01-12 2023-07-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
CN116478150A (zh) * 2022-01-21 2023-07-25 中国科学院上海药物研究所 具有ripk1抑制活性的化合物、其制备方法及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI637951B (zh) 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
TWI763630B (zh) 2015-07-02 2022-05-11 瑞士商赫孚孟拉羅股份公司 雙環內醯胺及其使用方法
CN108431004B (zh) 2015-10-23 2021-02-12 武田药品工业株式会社 杂环化合物
CR20180413A (es) * 2016-02-05 2018-12-04 Denali Therapeutics Inc Inhibidores de la proteína quinasa 1 que interactua con el receptor
EP3645525A1 (en) * 2017-06-29 2020-05-06 Rigel Pharmaceuticals, Inc. Kinase inhibitors and methods for making and using
WO2019204537A1 (en) * 2018-04-20 2019-10-24 Genentech, Inc. N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
SG11202010913PA (en) 2018-05-03 2020-12-30 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same
HUE063896T2 (hu) 2018-05-03 2024-02-28 Rigel Pharmaceuticals Inc RIP1 inhibitorvegyületek, valamint ezek elõállítása és alkalmazása
KR20210024574A (ko) 2018-06-26 2021-03-05 상하이 인스티튜트 오브 오가닉 케미스트리, 차이니즈 아카데미 오브 사이언시스 세포 괴사 억제제 및 이의 제조 방법과 용도
CN109134448B (zh) * 2018-10-16 2020-11-27 中南大学湘雅医院 杂环化合物及其盐、制备方法、用途和药物
CN111138448B (zh) 2018-11-02 2022-08-02 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
CN114008038B (zh) 2019-05-31 2023-01-24 南京明德新药研发有限公司 作为rip-1激酶抑制剂的双并环类化合物及其应用
PE20221628A1 (es) 2019-09-06 2022-10-19 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos
KR20220079919A (ko) 2019-11-07 2022-06-14 리겔 파마슈티칼스, 인크. 헤테로시클릭 rip1 억제 화합물

Also Published As

Publication number Publication date
IL296916A (en) 2022-12-01
MX2022012305A (es) 2023-03-06
US20230227469A1 (en) 2023-07-20
BR112022019492A2 (pt) 2022-11-16
TW202204364A (zh) 2022-02-01
EP4126864A1 (en) 2023-02-08
US20210317135A1 (en) 2021-10-14
AU2021246147A1 (en) 2022-10-20
CA3173432A1 (en) 2021-10-07
WO2021203011A1 (en) 2021-10-07
JP2023520046A (ja) 2023-05-15
KR20220161433A (ko) 2022-12-06
CN115867548A (zh) 2023-03-28
DOP2022000215A (es) 2023-02-28
CR20220492A (es) 2023-02-09
PE20230560A1 (es) 2023-03-31
AU2021246147B2 (en) 2024-01-18
CO2022014137A2 (es) 2023-03-07
JOP20220246A1 (ar) 2023-01-30
US11584758B2 (en) 2023-02-21
ECSP22076856A (es) 2023-02-28
AR121717A1 (es) 2022-06-29

Similar Documents

Publication Publication Date Title
DOP2022000051A (es) Compuestos inhibidores de rip1 y métodos para hacer y utilizar los mismos
CO2020015156A2 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos referencia cruzada a una solicitud relacionada
CL2022002695A1 (es) Inhibidores de rip1k
ECSP20077518A (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
DOP2022000042A (es) Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
CL2019000819A1 (es) Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2022003812A1 (es) Inhibidores de rip1k
CO2023012077A2 (es) Inhibidores heterocíclicos de la cinasa rip1
AR120412A1 (es) Compuestos heterocíclicos inhibidores de rip1